Melatonin receptors in PC3 human prostate tumor cells

Area of Science:

• Endocrinology
• Molecular Biology
• Oncology

Background:

• Melatonin, a pineal gland hormone, influences benign prostate epithelial cells.
• The interaction of melatonin with hormone-insensitive prostate tumor cells remains largely unexplored.
• Understanding melatonin's role in prostate cancer progression is crucial for therapeutic development.

Purpose of the Study:

• To investigate melatonin binding and its functional effects on human PC3 prostate tumor cells.
• To elucidate the signaling pathways involved in melatonin's action in these cells.
• To determine the influence of cell density on melatonin's effects.

Main Methods:

• Radioligand binding assays using 125I-melatonin to determine receptor affinity (Kd).
• Measurement of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels.
• Assessment of 3H-thymidine incorporation and cell count to evaluate cell proliferation.
• Pertussis toxin and cholera toxin treatments to identify G protein involvement.
• Pharmacological inhibition using 8-Br-cGMP and H89 (protein kinase A inhibitor).

Main Results:

• PC3 cells exhibit low-affinity binding of 125I-melatonin.
• Melatonin's effects on cAMP, cGMP, 3H-thymidine incorporation, and cell count are cell density-dependent.
• Pertussis toxin-sensitive G proteins mediate melatonin's effects on proliferation and cyclic nucleotide signaling.
• Cholera toxin partially blocks melatonin's modulation of cAMP and cGMP.
• cGMP analogs and protein kinase A inhibition partially affect melatonin's impact on proliferation.

Conclusions:

• This study demonstrates direct melatonin receptor interaction with hormone-insensitive PC3 prostate tumor cells.
• Melatonin signaling in PC3 cells involves pertussis toxin-sensitive G proteins, leading to cell density-dependent effects on growth and cyclic nucleotides.
• These findings provide a basis for exploring melatonin as a potential therapeutic agent in prostate cancer.